In Figure 6A, we examined the differential sensitivity of SOX2-high and SOX2-low MCF7 cells sub-populations to 4-OH-Tamoxifen, an FDA-approved drug used in ER (+) breast cancer cells treatment. The gene discussed is SOX2; the disease is breast carcinoma.